← Back to Clinical Trials
Recruiting NCT06167369

NCT06167369 Biological and Cognitive Marker of Neurodegeneration in Obstructive Sleep Apnea Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06167369
Status Recruiting
Phase
Sponsor Technische Universität Dresden
Condition Sleep Apnea, Obstructive
Study Type OBSERVATIONAL
Enrollment 136 participants
Start Date 2024-01-01
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 136 participants in total. It began in 2024-01-01 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to investigate biomarkers and neurocognitive markers of neurodegenerative processes in obstructive sleep apnea patients. The main questions the study aims to answer are: * Does neurodegeneration assessed by neurobiological markers and neurocognitive test performance exists in obstructive sleep apnea? * Are these neurodegenerative markers are associated with the adherence to clinical prescribed positive airway pressure therapy? Newly diagnosed patients with obstructive sleep apnea will be observed during the use of clinical prescribed positive pressure therapy. Different study related investigations take place before and six months after treatment start. Researchers will compare after six months the group of adherent treatment participants with the non-adherent treatment participants group to investigate if differences in the observed neurobiological or neurocognitive parameters exist.

Eligibility Criteria

Inclusion Criteria: * newly diagnosed obstructive sleep apnea * clinical indication for start of positive airwas pressure therapy * Age older than 18 years Exclusion Criteria: * neurodegenerative disease * Multiple sclerosis * Stroke within last 3 months * Brain injury within last 3 months * MoCA \< 21 points * higher degree chonic kidney disease (lower than 30 mL/min) * regular use of sleep pills (e.g. Zopiclon, Mirtazapin, Daridorexant)

Contact & Investigator

Central Contact

Tony Sehr, MD

✉ tony.sehr@ukdd.de

📞 +49 351 458 19324

Frequently Asked Questions

Who can join the NCT06167369 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Sleep Apnea, Obstructive. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06167369 currently recruiting?

Yes, NCT06167369 is actively recruiting participants. Contact the research team at tony.sehr@ukdd.de for enrollment information.

Where is the NCT06167369 trial being conducted?

This trial is being conducted at Dresden, Germany.

Who is sponsoring the NCT06167369 clinical trial?

NCT06167369 is sponsored by Technische Universität Dresden. The trial plans to enroll 136 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology